Bridge to decision using the Levitronix CentriMag short-term ventricular assist device

Area of Science:

• Cardiovascular Surgery
• Mechanical Circulatory Support
• Critical Care Medicine

Background:

• Ventricular assist devices (VADs) are crucial for end-stage cardiac failure, but outcomes in critically ill patients remain challenging.
• Short-term, less invasive VADs are increasingly used for temporary support in severe cases.
• The Levitronix CentriMag device offers a potential solution for bridging decisions in high-risk cardiac patients.

Purpose of the Study:

• To evaluate the efficacy of the Levitronix CentriMag short-term ventricular assist device as a bridge-to-decision strategy.
• To assess the device's role in optimizing critically ill patients before committing to long-term VADs or cardiac transplantation.
• To determine the cost-effectiveness and survival benefits of using the CentriMag in moribund patients.

Main Methods:

• A cohort of 16 moribund patients (mean age 32.7 years) with severe cardiac failure were supported by the Levitronix CentriMag.
• Patients often presented with pre-operative intra-aortic balloon pump support, multi-organ failure, and septic shock.
• The device served as a 'bridge to decision' for subsequent treatment pathways.

Main Results:

• The Levitronix CentriMag demonstrated no device failures during its utilization.
• Actuarial survival rates at 1, 6, and 12 months were 85.7%, 64.9%, and 64.9%, respectively.
• Of the 11 surviving patients (68.7%), 2 recovered and had the device explanted, 6 were upgraded to long-term VADs, and 3 were bridged to transplantation.

Conclusions:

• The Levitronix CentriMag is effective in rescuing critically ill patients, providing essential low-cost support.
• It allows for patient optimization, enabling better selection for advanced interventions like expensive VADs or transplantation.
• This strategy improves the management of severe cardiac failure by facilitating informed therapeutic decisions.